| scholarly article | Q13442814 |
| P2093 | author name string | J R Chapman | |
| P2860 | cites work | Oral cyclosporine but not tacrolimus reduces renal transplant blood flow | Q44913861 |
| Cyclosporine withdrawal improves long-term graft survival in renal transplantation. | Q45960172 | ||
| Chronic renal failure after transplantation of a nonrenal organ | Q28204928 | ||
| Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials | Q33371189 | ||
| Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues | Q33392107 | ||
| Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study | Q33521348 | ||
| Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. | Q34181871 | ||
| Cyclosporin A in patients receiving renal allografts from cadaver donors | Q34347891 | ||
| International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology | Q34354852 | ||
| Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology? | Q35711160 | ||
| Chronic renal allograft dysfunction | Q36240051 | ||
| Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence | Q36653136 | ||
| Protocol transplant biopsies: an underutilized tool in kidney transplantation | Q36910301 | ||
| Therapeutic approach to focal and segmental glomerulosclerosis recurrence in kidney transplant recipients | Q37764126 | ||
| Cyclosporin and renal graft histology | Q39558964 | ||
| The natural history of chronic allograft nephropathy | Q44688416 | ||
| Determinants of long-term graft outcome in transplant glomerulopathy. | Q44697067 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 693-697 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Chronic calcineurin inhibitor nephrotoxicity-lest we forget | |
| P478 | volume | 11 |
| Q64055936 | A Case of Rheumatoid Arthritis Presenting with Renal Thrombotic Microangiopathy Probably due to a Combination of Chronic Tacrolimus Arteriolopathy and Severe Hypertension |
| Q35805955 | A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology |
| Q38041260 | A drug safety evaluation of everolimus in kidney transplantation |
| Q38544529 | Advances in pharmacotherapy to treat kidney transplant rejection |
| Q40220124 | An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade |
| Q53482976 | Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity. |
| Q58604348 | Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression |
| Q50212034 | Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation |
| Q56897769 | Belatacept: a novel immunosuppressive agent for kidney transplant recipients |
| Q51238482 | Calcineurin inhibitor conversion to rapamycin can improve graft function in living donor kidney transplantation with older donors. |
| Q38230449 | Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies |
| Q38027593 | Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials. |
| Q90201282 | Calcineurin inhibitors augment endothelial-to-mesenchymal transition by enhancing proliferation in association with cytokine-mediated activation |
| Q36908763 | Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol |
| Q90259050 | Causes of late transplant failure in cyclosporine-treated kidney allograft recipients |
| Q36365811 | Challenges and considerations in diagnosing the kidney disease in deteriorating graft function |
| Q38091657 | Ciclosporin use during pregnancy |
| Q37974480 | Clinical role of the renal transplant biopsy |
| Q38241710 | Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients |
| Q92435177 | Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biopsy |
| Q51744862 | Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies. |
| Q38096463 | Current pharmacotherapeutical options for the prevention of kidney transplant rejection |
| Q42777770 | Defining a microRNA-mRNA interaction map for calcineurin inhibitor induced nephrotoxicity |
| Q56970934 | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant p |
| Q53025046 | Different effects of tacrolimus and cyclosporine on PDGF induction and chronic allograft injury: evidence for improved kidney graft outcome. |
| Q64946985 | Does Rabbit Antithymocyte Globulin (Thymoglobuline®) Have a Role in Avoiding Delayed Graft Function in the Modern Era of Kidney Transplantation? |
| Q85930864 | Dopamine and noradrenaline are unrelated to renalase, heart rate, and blood pressure in heart transplant recipients |
| Q48242270 | Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study. |
| Q53803179 | Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors. |
| Q36255504 | Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials |
| Q40132359 | Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study. |
| Q28484671 | Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat |
| Q59360993 | Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation |
| Q26825480 | Factors influencing long-term outcome after kidney transplantation |
| Q35653607 | Functional and histological improvement after everolimus rescue of chronic allograft dysfunction in renal transplant recipients |
| Q38786239 | Generation of Insulin-Producing Cells From Human-Induced Pluripotent Stem Cells Using a Stepwise Differentiation Protocol Optimized With Platelet-Rich Plasma |
| Q45874681 | Generation of insulin-producing cells from human adipose-derived mesenchymal stem cells on PVA scaffold by optimized differentiation protocol. |
| Q38429887 | Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival |
| Q52803938 | Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression. |
| Q87342524 | Immunophenotyping of peripheral immunoregulatory as well as Th17A and Th22 cell subpopulations in kidney transplant recipients under belatacept or cyclosporine treatment |
| Q39523192 | Immunosuppressive properties of a series of novel inhibitors of the monocarboxylate transporter MCT-1. |
| Q101119457 | Impact of Immunosuppressive Strategies on Post-Kidney Transplantation Thrombocytopenia |
| Q54411021 | Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. |
| Q44033348 | Improvement of renal graft function after conversion from a calcineurin inhibitor including immunosuppression to a mycophenolate sodium including regimen: a 4-year follow-up |
| Q40707474 | Incidence and risk factors for herpes zoster in patients undergoing liver transplantation |
| Q45910333 | Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4α senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A. |
| Q40441376 | Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation. |
| Q34437449 | Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection |
| Q38156847 | Is it time to give up with calcineurin inhibitors in kidney transplantation? |
| Q47758005 | Kidney involvement in psoriasis: a case-control study from China. |
| Q41834576 | Late kidney dysfunction in a kidney transplant recipient |
| Q40015538 | Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience |
| Q38044776 | Metabolic syndrome in patients with hematological diseases. |
| Q50592626 | MicroRNA-494 promotes cyclosporine-induced nephrotoxicity and epithelial to mesenchymal transition by inhibiting PTEN. |
| Q42010223 | N-Octanoyl dopamine transiently inhibits T cell proliferation via G1 cell-cycle arrest and inhibition of redox-dependent transcription factors |
| Q83828754 | New-onset diabetes mellitus in cyclosporine-treated organ transplant patients in Taiwan: interim analysis (6 months) of postmarketing surveillance |
| Q57151742 | Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation |
| Q47617412 | Permanent CNI treatment for prevention of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells |
| Q34551797 | Prolonged, low-dose anti-thymocyte globulin, combined with CTLA4-Ig, promotes engraftment in a stringent transplant model |
| Q51019985 | Recurrence of diabetic kidney disease in a type 1 diabetic patient after kidney transplantation. |
| Q42679895 | Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. |
| Q52874072 | Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. |
| Q44911053 | Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma |
| Q54613737 | Risk Factors Associated With Mammalian Target of Rapamycin Inhibitor Withdrawal in Kidney Transplant Recipients. |
| Q53675239 | Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature. |
| Q40249744 | Serum and renal tissue markers of nephropathy in rats under immunosuppressive therapy: cyclosporine versus sirolimus. |
| Q39340117 | Strategies for long-term preservation of kidney graft function |
| Q34243189 | Structure-based optimization of a peptidyl inhibitor against calcineurin-nuclear factor of activated T cell (NFAT) interaction |
| Q35910134 | Successful pregnancy after simultaneous pancreas-kidney transplantation |
| Q28554254 | The Spectrum of Renal Allograft Failure |
| Q38370826 | The need for minimization strategies: current problems of immunosuppression. |
| Q56761713 | The spectrum of renal abnormalities in patients with psoriasis |
| Q33755928 | Transition from cyclosporine-induced renal dysfunction to nephrotoxicity in an in vivo rat model |
Search more.